Can I Take Melatonin with Tresiba (Insulin Degludec)?

What Is the Interaction Between Melatonin and Tresiba?

The interaction is pharmacodynamic, not pharmacokinetic. Tresiba is metabolized by proteolytic degradation rather than cytochrome P450 enzymes, so melatonin does not change how much Tresiba reaches the bloodstream or how fast it is cleared [1]. The concern sits at the level of blood glucose control itself.

Melatonin acts on MT1 and MT2 receptors expressed on pancreatic beta cells. Activation of these receptors reduces intracellular cyclic AMP and cyclic GMP, which suppresses glucose-stimulated insulin secretion [2]. When endogenous insulin secretion falls, the exogenous insulin supplied by Tresiba must cover a larger fraction of the glucose load. If the Tresiba dose was calibrated before melatonin was added, blood sugar may run higher overnight.

A secondary effect runs in the opposite direction. In some people, melatonin shifts glucose into storage by acting on peripheral tissues, which could theoretically add to Tresiba's glucose-lowering effect and increase hypoglycemia risk [3]. The net clinical result varies by individual, which is exactly why glucose monitoring matters during the first two weeks.

Why the Pharmacokinetics of Tresiba Matter Here

Tresiba forms subcutaneous multi-hexamer chains after injection. Those chains slowly dissolve, producing a flat, peakless insulin action that lasts beyond 42 hours at steady state [1]. Because there is no pronounced overnight peak, Tresiba itself rarely causes the sharp nocturnal hypoglycemia seen with NPH or insulin glargine U-100. Adding melatonin does not change that flat profile, but any glucose-raising effect of melatonin could be masked until morning fasting checks reveal a pattern of elevated readings.

The MT2 Receptor Genotype Factor

Genome-wide association studies have identified variants in the MTNR1B gene (encoding the MT2 receptor) as among the strongest common genetic risk factors for type 2 diabetes [4]. Carriers of the MTNR1B risk allele show a more pronounced suppression of insulin secretion in response to melatonin. A 2022 study in Diabetes Care (N=1,068) found that evening melatonin use in MTNR1B risk-allele carriers was associated with a 0.19 mmol/L higher fasting glucose compared with non-carriers on placebo [5]. Most people do not know their MTNR1B genotype, so treating any melatonin addition as a glucose-monitoring event is reasonable clinical practice.

What Does the Research Say About Melatonin and Blood Sugar?

Evidence is mixed but points in a consistent direction at higher doses. A randomized crossover trial published in JAMA Network Open (N=105 adults at risk for type 2 diabetes) found that 10 mg of melatonin taken with a glucose challenge raised two-hour glucose by 6.6% compared with placebo (P<0.01) [6]. That effect was amplified roughly threefold in MTNR1B risk-allele carriers [6].

Lower doses show less impact. A 2021 meta-analysis in Nutrition Reviews (8 RCTs, N=383) reported no statistically significant change in fasting insulin or HOMA-IR with melatonin doses at or below 2 mg, although directional effects still favored slight insulin suppression [7]. Dose matters.

Animal and Mechanistic Data

Rat islet studies demonstrate that 1 nmol/L melatonin reduces glucose-stimulated insulin secretion by approximately 30% through Gi-protein-coupled MT2 receptor signaling [2]. Human beta cell line data published in the Journal of Pineal Research replicated the cAMP suppression finding at physiologically relevant nocturnal melatonin concentrations, around 100 to 300 pmol/L [8]. Exogenous melatonin supplements at 3 to 10 mg produce plasma levels far above that range, potentially amplifying the suppressive effect on whatever endogenous secretory capacity remains in people with diabetes [9].

Sleep Deprivation, Melatonin, and Insulin Resistance

Poor sleep itself causes insulin resistance. A controlled in-laboratory study in Annals of Internal Medicine (N=9 healthy adults) showed that four nights of 4.5 hours of sleep reduced insulin sensitivity by 16% [10]. If melatonin reliably improves sleep architecture, any glucose-raising effect from beta-cell suppression might be partially offset by reduced sleep-deprivation-related insulin resistance. That trade-off has not been formally tested in people using basal insulin specifically, and this uncertainty is part of why monitoring is the safest path.

How Should You Time Melatonin If You Are Using Tresiba?

Tresiba is designed as a once-daily injection with flexible timing, though Novo Nordisk's FDA-approved prescribing information states that doses should not be spaced fewer than 8 hours apart [1]. Most people inject Tresiba in the evening before dinner or at bedtime. Melatonin is typically taken 30 to 60 minutes before sleep.

Practical Timing Guidance

Taking melatonin 30 minutes before bed, after the Tresiba injection has already been administered and absorbed into the subcutaneous depot, does not alter Tresiba's absorption kinetics [1]. The two can be used on the same evening without a mandatory separation window. The concern is not timing of absorption but the downstream pharmacodynamic effect on overnight glucose.

Check blood glucose immediately before bed and again at fasting in the morning for the first 14 days after starting melatonin. A fasting glucose consistently above 180 mg/dL may mean melatonin is blunting residual endogenous insulin secretion enough to require a Tresiba dose review. A fasting glucose below 70 mg/dL on two or more mornings warrants a call to your prescriber before the next dose.

Dose Selection

The American Academy of Sleep Medicine's 2023 clinical practice guideline on chronic insomnia does not endorse melatonin as first-line therapy for chronic insomnia disorder but acknowledges its use for circadian rhythm disorders [11]. For general sleep-onset difficulty, the lowest effective dose is 0.5 mg. The endogenous nocturnal peak of melatonin in healthy adults is approximately 100 to 150 pg/mL; a 0.5 mg oral dose raises plasma melatonin roughly 10-fold above that peak, while a 10 mg dose raises it more than 100-fold [9]. There is no pharmacological reason for most adults to take more than 1 to 3 mg, and people on basal insulin have added reason to stay at the lower end.

Is Tresiba's Glucose-Lowering Effect Changed by Melatonin?

Tresiba's own pharmacodynamic profile is not changed by melatonin. The glucose infusion rate curves in Tresiba's Phase III program, including the BEGIN trials (BEGIN Basal-Bolus Type 1, N=629; BEGIN Once Long Type 2, N=1,030), were generated without melatonin co-administration, so no head-to-head data exist [12][13]. What changes is the glucose environment in which Tresiba operates.

If melatonin raises fasting glucose by several mg/dL through beta-cell suppression, the net effect is that Tresiba's fixed dose covers less of the total glucose load. The insulin itself is working exactly as expected. The glucose is just higher. That distinction matters because the fix is a conversation about whether the Tresiba dose or the melatonin dose needs adjustment, not a conclusion that the two drugs are incompatible.

BEGIN Trial Benchmarks for Reference

In BEGIN Once Long Type 2 (N=1,030, 52 weeks), insulin degludec reduced HbA1c by 1.06 percentage points from a baseline of 8.2%, with a fasting plasma glucose of 108 mg/dL at week 52 in the degludec arm [13]. Any consistent melatonin-related rise in fasting glucose above the 108 mg/dL benchmark achieved in that trial would be clinically meaningful and worth discussing with your care team.

Who Faces the Highest Risk from This Combination?

Several patient profiles warrant more caution.

People with type 1 diabetes have no residual beta-cell function, so melatonin's suppression of endogenous insulin secretion is largely irrelevant. The primary risk in type 1 is whether melatonin-driven changes in peripheral glucose metabolism (the counter-regulatory direction) could increase hypoglycemia overnight. This is a theoretical concern without strong clinical trial evidence, but vigilance with CGM is sensible [3].

People with type 2 diabetes who retain some beta-cell function face the opposite risk. Melatonin suppresses whatever residual secretion they have, potentially raising fasting glucose and HbA1c over weeks of regular use.

People carrying MTNR1B risk alleles. As noted in the Diabetes Care study cited above, these individuals show a more pronounced glycemic response to evening melatonin [5]. Genetic testing for MTNR1B is available through several direct-to-consumer and clinical genomics platforms but is not standard of care.

People on high-dose melatonin (5 to 10 mg). The pharmacodynamic signal in trials is most consistent at doses of 5 mg and above [6]. Staying at 0.5 to 1 mg reduces but does not eliminate this risk.

Drug Interactions That Compound the Picture

Tresiba's FDA label lists several drug classes that can potentiate or blunt insulin action [1]. Antidiabetic agents, beta-blockers, ACE inhibitors, and salicylates can potentiate glucose lowering; corticosteroids, atypical antipsychotics, and diuretics can blunt it. Melatonin itself does not appear on that label, but the combined glucose-disrupting potential of, for example, melatonin plus a high-dose corticosteroid burst in a Tresiba user is additive and unpredictable without monitoring.

What Should You Tell Your Prescriber?

Be specific. Bring the melatonin product label showing the dose per tablet, the brand name or manufacturer, and how often you plan to take it. Some products are 10 mg when 0.5 mg would achieve the same effect, simply because higher-dose tablets are more commonly stocked at retail pharmacies.

The American Diabetes Association's Standards of Care in Diabetes (2024) states: "The use of dietary supplements is not recommended for glycemic management in people with diabetes due to a lack of evidence of benefit and concern for harm." [14] That position applies to melatonin used as a glycemic agent, not necessarily to melatonin used for short-term sleep support, but it signals that your diabetes care team should be in the loop.

A simple framework for the prescriber conversation:

1. State the sleep problem (difficulty falling asleep vs. Staying asleep vs. Early waking), duration, and any prior treatments tried.
2. Report your current Tresiba dose, injection time, and recent fasting glucose range.
3. Ask specifically about starting at 0.5 mg melatonin rather than the standard retail 5 or 10 mg.
4. Agree on a monitoring plan: glucose checks at bedtime and fasting for 14 days, with a follow-up message or call if fasting glucose shifts by more than 20 mg/dL from your usual baseline.
5. Revisit at 30 days to assess whether the melatonin is helping sleep without worsening glycemic control.

Monitoring Glucose While Using Both

Continuous glucose monitors (CGM) offer the clearest picture. Devices such as the Dexterity Libre 3 or Dexterity G7 generate overnight trend graphs that make a melatonin-driven rise in fasting glucose visible without requiring multiple fingerstick checks. If you use a CGM, export your overnight trend data for the week before and the two weeks after starting melatonin and share it with your prescriber.

Without CGM, a minimum monitoring schedule is:

• Bedtime glucose before the melatonin dose (target 90 to 130 mg/dL per ADA 2024 guidelines) [14]
• Fasting glucose each morning (target 80 to 130 mg/dL) [14]
• A 3 AM glucose check on two or three nights during the first week if hypoglycemia is a concern

The FDA's MedWatch program collects voluntary adverse event reports. As of the 2024 Tresiba prescribing update, no formal interaction study between insulin degludec and melatonin has been conducted and listed [1]. That absence of data is not evidence of safety; it reflects the general under-study of supplement-drug interactions in regulated clinical trials.

Signs That the Combination Is Not Working for You

Call your prescriber if you notice fasting glucose readings above 180 mg/dL on three or more consecutive mornings after starting melatonin, any symptomatic hypoglycemia (shakiness, sweating, confusion) upon waking, or a change in your time-in-range percentage of more than 10 percentage points on CGM. Each of these suggests that your Tresiba dose or your melatonin dose needs recalibration, not that you must choose one or the other.

Adjust the melatonin dose first before adjusting Tresiba, because melatonin is the new variable. Drop from 5 mg to 1 mg, or from 1 mg to 0.5 mg, and repeat the 14-day monitoring cycle. If glucose returns to your prior baseline at the lower melatonin dose, that is diagnostic: the original dose was pharmacodynamically active on your glucose homeostasis.